Valuation: Alkermes plc

Market Cap 8.79B 7.68B 7.09B 6.53B 12.31B 846B 12.58B 84.7B 33.31B 414B 33B 32.28B 1,427B P/E 2026 *
-137x
P/E 2027 * 90.5x
Enterprise Value 9.8B 8.56B 7.9B 7.28B 13.72B 943B 14.03B 94.42B 37.14B 462B 36.79B 35.98B 1,590B EV / Sales 2026 *
5.41x
EV / Sales 2027 * 5.05x
Free-Float
89.39%
Yield 2026 *
-
Yield 2027 * -
1 day+1.50%
1 week+1.50%
Current month+0.62%
1 month+17.18%
3 months+52.68%
6 months+66.68%
Current year+88.42%
1 week 50.49
Extreme 50.4855
53.52
1 month 45
Extreme 45.005
55.67
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 31/01/1991
Director of Finance/CFO 53 14/09/2025
Chief Tech/Sci/R&D Officer 58 29/05/2017
Director TitleAgeSince
Chairman 64 31/08/2011
Director/Board Member 74 25/05/2016
Director/Board Member 63 29/03/2018
Date Insider Type Main position Quantity % Market Cap.
06/07/26 Sell

Compliance Officer

-2,034 0.0012%
01/07/26 Fiscal year

Chief Technology Officer

19,000 0.0114%
12/06/26 Sell

Director

-2,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+1.50%+1.50%+80.42%+67.47% 8.79B
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average +0.20%+0.17%+67.58%+94.99% 25.24B
Weighted average by Cap. +0.00%-0.12%+79.48%+121.24%

Financials

2026 *2027 *
Net sales 1.81B 1.58B 1.46B 1.34B 2.53B 174B 2.59B 17.44B 6.86B 85.34B 6.79B 6.65B 294B 1.89B 1.65B 1.52B 1.4B 2.65B 182B 2.71B 18.21B 7.16B 89.12B 7.1B 6.94B 307B
Net income -64.46M -56.33M -51.98M -47.91M -90.3M -6.21B -92.31M -621M -244M -3.04B -242M -237M -10.47B 99.47M 86.93M 80.22M 73.94M 139M 9.58B 142M 959M 377M 4.69B 374M 365M 16.15B
Net Debt 1.01B 881M 813M 750M 1.41B 97.11B 1.44B 9.72B 3.82B 47.56B 3.79B 3.7B 164B 757M 662M 611M 563M 1.06B 72.94B 1.08B 7.3B 2.87B 35.72B 2.84B 2.78B 123B
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
17/07/26 US$52.72 +1.50% 1,713,653
16/07/26 US$51.94 -0.08% 1,843,684
15/07/26 US$51.98 +0.74% 1,556,270
14/07/26 US$51.60 -0.52% 1,776,619
13/07/26 US$51.87 -0.13% 1,583,838
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
52.72USD
Average target price
51.59USD
Spread / Average Target
-2.15%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock